Preclinical evaluation of lime juice as a topical microbicide candidate. by Fletcher, Patricia S et al.
Fletcher, PS; Harman, SJ; Boothe, AR; Doncel, GF; Shattock, RJ
(2008) Preclinical evaluation of lime juice as a topical microbicide can-
didate. Retrovirology, 5. p. 3. ISSN 1742-4690 DOI: https://doi.org/10.1186/1742-
4690-5-3
Downloaded from: http://researchonline.lshtm.ac.uk/4645776/
DOI: 10.1186/1742-4690-5-3
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
BioMed Central
Page 1 of 10
(page number not for citation purposes)
Retrovirology
Open AccessResearch
Preclinical evaluation of lime juice as a topical microbicide 
candidate
Patricia S Fletcher1, Sarah J Harman1, Adrienne R Boothe2, 
Gustavo F Doncel2 and Robin J Shattock*1
Address: 1St George's University of London, UK and 2CONRAD, Eastern Virginia Medical School, USA
Email: Patricia S Fletcher - pfletche@sgul.ac.uk; Sarah J Harman - sharman@sgul.ac.uk; Adrienne R Boothe - BootheAR@evms.edu; 
Gustavo F Doncel - DoncelGF@evms.edu; Robin J Shattock* - shattock@sgul.ac.uk
* Corresponding author    
Abstract
Background: The continued growth of the global HIV epidemic highlights the urgent need to
develop novel prevention strategies to reduce HIV transmission. The development of topical
microbicides is likely to take a number of years before such a product would be widely available.
This has resulted in a call for the rapid introduction of simpler vaginal intervention strategies in the
interim period. One suggested practice would be vaginal douching with natural products including
lime or lemon juice. Here we present a comprehensive preclinical evaluation of lime juice (LiJ) as a
potential intervention strategy against HIV.
Results: Pre-treatment of HIV with LiJ demonstrated direct virucidal activity, with 10% juice
inactivating the virus within 5 minutes. However, this activity was significantly reduced in the
presence of seminal plasma, where inactivation required maintaining a 1:1 mixture of neat LiJ and
seminal plasma for more than 5 minutes. Additionally, LiJ demonstrated both time and dose-
dependent toxicity towards cervicovaginal epithelium, where exposure to 50% juice caused 75–
90% toxicity within 5 minutes increasing to 95% by 30 minutes. Cervicovaginal epithelial cell
monolayers were more susceptible to the effects of LiJ with 8.8% juice causing 50% toxicity after 5
minutes. Reconstructed stratified cervicovaginal epithelium appeared more resilient to LiJ toxicity
with 30 minutes exposure to 50% LiJ having little effect on viability. However viability was reduced
by 75% and 90% following 60 and 120 minutes exposure. Furthermore, repeat application (several
times daily) of 25% LiJ caused 80–90% reduction in viability.
Conclusion: These data demonstrate that the virucidal activity of LiJ is severely compromised in
the presence of seminal plasma. Potentially, to be effective against HIV in vivo, women would need
to apply a volume of neat LiJ equal to that of an ejaculate, and maintain this ratio vaginally for 5–30
minutes after ejaculation. Data presented here suggest that this would have significant adverse
effects on the genital mucosa. These data raise serious questions about the plausibility and safety
of such a prevention approach.
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Background
Women are increasingly bearing the brunt of the global
HIV epidemic, accounting for 50% of cases worldwide
and >67% of cases in sub-Saharan Africa where three
times more 15–24 year old women are infected than men
[1]. The mantra of "abstinence, faithfulness and con-
doms" appears to be failing these vulnerable groups
where men often refuse to use condoms and faithfulness
only works if practiced by both partners [2]. The lack of
alternative protection options available to women has led
to the use of traditional practices such as vaginal douching
with water, soap or acidic solutions in the belief that this
may prevent HIV infection.
For an intervention strategy against HIV transmission to
be effective it needs to fulfil criteria associated with cost,
availability, acceptability, safety and efficacy [3,4]. The
urgent need for the development of female-initiated strat-
egies to prevent HIV-1 transmission has been the basis for
international efforts to develop vaginal microbicides [4].
However, the timelines for the development of an effec-
tive microbicide (5–10 years) have led some to question
whether simpler strategies using readily available natural
products such as limes or lemons, might allow a more
rapid introduction of a vaginal intervention strategy that
could prevent infection even if only partially effective.
Limes are cheap and readily accessible throughout all
tropical and temperate regions of the globe [5], and thus
are probably accessible to the majority of the world's pop-
ulation. Therefore they most likely fit the first three criteria
of an effective intervention strategy (cheap, available,
acceptable), however little is known about the other crite-
ria – safety and efficacy.
The hypothesis that lime/lemon douching might prevent
HIV transmission is based upon existing data showing
that a pH <4.5 is sufficient to inactivate HIV in vitro [6].
Therefore, maintenance of a low pH (<4.0) has been the
basis of several intervention strategies, specifically the
development of acid buffering gels including BufferGel
[7,8], which is currently in phase IIb clinical trials, and
ACIDFORM [9], currently in phase I clinical trials. Recent
data, however, indicate that non-clade B primary HIV-1
isolates may be less susceptible to low pH than the lab-
adapted clade B viruses used in previous studies [10].
There is a long reported history of African women douch-
ing with lime juice (LiJ), lemon juice (LeJ), vinegar or
acidic soft drinks in the belief that it may prevent preg-
nancy and/or sexually transmitted diseases (STDS) [5].
This suggests that should such practices be effective, they
could be rapidly implemented. However the frequency
and geographical distribution of such practices across
Africa and other areas of the world with high HIV preva-
lence has not been systematically evaluated. More impor-
tantly, the impact of such practices on HIV transmission
rates (positive or negative) has not been assessed. A recent
survey of female sex workers (FSW) in the city of Jos,
Nigeria reported that up to 80% of them regularly used
LiJ/LeJ douches either before or after sex, and of those
68.6% used lime, 19.6% lemon and 11.8% used both
[11]. A previous pilot study on a similar population of
commercial FSW has shown that the most common
method of using LiJ is to mix the juice from 1–4 limes
with 1–4 teaspoons of water and douche with the result-
ing solution, but practices range from mixing the juice of
one lime with one cup of water to mixing the juice of four
limes with one teaspoon of water [12].
As LiJ has been evaluated in phase I clinical trials to assess
its safety as a potential intervention strategy against HIV
transmission, and its use may have already been adopted
by women at risk of HIV infection, we have undertaken
preclinical in vitro studies to assess the potential safety and
efficacy of LiJ using cellular and ex vivo mucosal tissue
models.
Results
Virucidal activity of lime juice
To determine whether LiJ exhibited virucidal properties,
HIV-1BaL was pre-treated with 5 or 10% LiJ (diluted using
RPMI 1640 + 10% fetal bovine serum [RPMI 10%]) for 5,
30, 60 or 120 minutes prior to application onto human
cervicovaginal tissue explants. To minimise the toxicity of
LiJ to the cultured tissue, the virus/LiJ mixture was diluted
1/10 using RPMI 10% prior to tissue exposure. Following
a 2 hour exposure to virus/LiJ, cervicovaginal tissue was
washed and cultured for 10 days when viral infection was
determined by the release of p24 antigen in the culture
supernatants. To ensure that any lack of infection in cervi-
covaginal tissue was not due to LiJ toxicity, additional
explants were exposed to equivalent LiJ concentrations for
2 hours and assessed for viability in parallel. Those con-
centrations of LiJ demonstrating more than 25% toxicity
were not evaluated for HIV infection. On this basis, con-
centrations above 10% (i.e., 1% following the 1/10 dilu-
tion performed prior to exposure) could not be evaluated
due to their significant toxic effects on cervicovaginal tis-
sue (data not shown). At 5%, LiJ was seen to exhibit viru-
cidal activity in a time-dependent manner, needing 60
minutes to completely inhibit viral infectivity (Figure 1).
Five minutes, however, was sufficient for 10% LiJ diluted
in culture medium to completely inactivate the virus.
Virucidal activity in the presence of semen
Although LiJ was shown to have virucidal activity against
HIV-1 infection of cervicovaginal explants, it was impor-
tant to determine the virucidal activity in the presence of
semen, the natural carrier of the virus during sexual trans-
mission. This was completed using T cells and microplate-
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immobilised virus. Immobilised HIV-1RF was treated with
LiJ in the absence or presence of 50 or 25% seminal
plasma (SP) for 5, 30 or 60 minutes. Following LiJ/SP
removal by washing, virus was then cultured with C8166
T cells for 7 days when viral replication was determined by
viral reverse transcriptase (RT) activity in culture superna-
tants. As had been observed using cervicovaginal explants,
LiJ diluted in saline (0.9% NaCl) was virucidal in both a
time and dose-dependent manner, with ≥ 5% LiJ inacti-
vating all virus after 30 minutes of incubation (Figure 2).
However, in the presence of SP, virucidal activity was sig-
nificantly reduced. In the absence of SP, 50% LiJ inacti-
vated 80% of the virus within 5 minutes. However, in the
presence of 25 or 50% SP, virus inactivation required LiJ
exposure for 30 minutes to have the same effect. This
effect was more noticeable with lower concentrations of
LiJ, with the virucidal activity of ≤ 25% LiJ being elimi-
nated by 50% SP. Furthermore, the presence of 25% SP
significantly prevented any virucidal activity of ≤ 10% LiJ.
Only a 30–60 minute treatment of virus with 50% LiJ in
the presence of 25 or 50% SP was sufficient to completely
inhibit HIV-1RF infection of T cells.
Toxicity of lime juice on human genital tissue
As the initial determinations of virucidal activity using
genital tissue had demonstrated that LiJ exhibited a poten-
tial toxic effect, any detrimental effects attributable to LiJ
application were evaluated further. Cervicovaginal and
penile tissue explants were exposed to LiJ (0.5–50%
diluted in normal saline) for 5, 30, 60 or 120 minutes and
toxicity determined using the principle of MTT dye reduc-
tion. Exposure to LiJ exhibited significant dose and time-
dependent toxic effects on genital tissue with similar
effects observed with both cervicovaginal (Figure 3A) and
penile tissue explants (Figure 3B). In general, increased
exposure times resulted in decreased 50% toxic dose
(TD50) values (Figure 3C), whilst low concentrations
(0.5–1%) of LiJ appeared non-toxic to genital tissue, even
following 120 minute exposure. However, as little as 5%
LiJ caused significant toxicity to genital tissue following
exposure times of 30 minutes or more. Furthermore, a 5
minute exposure to 50% LiJ caused a 75–90% reduction
in viability, and >95% reduction following a 30 minute
exposure period in both cervicovaginal and penile tissue
explants.
Toxicity of lime juice to cervical epithelial cells
The potential toxicity caused to the epithelium of the cer-
vix was evaluated using the cervical epithelial cell line
ME180. As previously, cells were exposed to LiJ diluted in
normal saline for 5, 30 or 60 minutes when cell viability
was then determined. Exposure of cervical epithelial cells
to LiJ again caused a significant toxic effect that was both
time and dose-dependent (Figure 4). Whilst treatment for
only 5 minutes caused a 50% reduction in viability at
8.8% juice, this decreased to 0.54% following 30 minutes,
and 0.16% following a 60 minute exposure.
Toxicity of lime juice application on the stratified 
cervicovaginal epithelium
To evaluate the effect of topical application of LiJ onto an
intact, stratified cervicovaginal epithelium, investigations
were completed using reconstructed cervicovaginal epi-
thelial cultures (MatTek Corp). Although the stratified cer-
vicovaginal epithelium appeared to be less susceptible
than mucosal genital tissue to the toxic effects of LiJ
(diluted in saline) following topical application, dose and
time-dependent effects were also observed (Figure 5).
Whilst there were no obvious signs of toxicity following a
5 or 30 minute treatment period with up to 50% LiJ, a sig-
nificant reduction in viability was observed following 60
minutes, with 50% LiJ causing a 75% reduction in viabil-
ity. Furthermore, a 2 hour exposure to 25% LiJ resulted in
65% reduction in viability and 50% LiJ caused 90% toxic-
ity. In contrast to genital tissue explants, a single topical
application of 5 or 10% LiJ to the stratified cervicovaginal
epithelium did not cause any obvious toxicity even when
exposure occurred for 2 hours.
Virucidal activity of lime juiceF gure 1
Virucidal activity of lime juice. HIV-1BaL (105 TCID50) 
was exposed to 5% (blue circles) or 10% (red circles) LiJ 
(diluted using RPMI 10% FBS) for 5 – 120 minutes. This HIV/
juice mix was then diluted 1/10 with RPMI 10% and applied 
to human cervicovaginal explants. Following 2 hours, 
explants were washed to remove juice and excess virus, and 
cultured for 10 days with 50% media feeds every 2–3 days. 
HIV-1 infection was determined by measurement of p24 Ag 
release into culture supernatants. Data shown are expressed 
as percentage infection (when compared to an untreated 
virus control) and represent the mean ± SEM of n = 3 inde-
pendent tissue donors where each condition was tested in 
triplicate.
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To investigate whether an intact stratified cervicovaginal
epithelium would be more susceptible to the toxic effects
of LiJ following multiple applications, reconstructed cer-
vicovaginal epithelial cultures were repeatedly exposed to
a topical application of LiJ. Multiple exposures occurred
either over one day (five 30 minute treatments followed
each time by a 60 minute culture period in the absence of
LiJ), or once a day for 5 days (30 minute exposure each
day, followed by overnight culture in the absence of LiJ).
Following either repeat treatment regime, the stratified
cervicovaginal epithelium appeared to be more suscepti-
ble to the toxic effects of LiJ in a dose and time-dependent
manner (Figure 6). Significant toxicity was observed fol-
lowing repeat application, with 25% LiJ causing 80–90%
reduction in viability. Whilst repeated application of 10%
LiJ throughout the course of one day caused a 60% reduc-
tion in epithelial viability, the same LiJ concentration
appeared non-toxic when applied once daily for 5 consec-
Virucidal activity of lime in the presence of semenF gure 2
Virucidal activity of lime in the presence of semen. Immobilised HIV-1RF (using poly L-lysine capture) was treated with 
LiJ (diluted in normal saline) in the absence (red circles/solid line) or presence of seminal plasma (50% seminal plasma: dark blue 
circles/dashed line; 25% seminal plasma: light blue circles/dotted line) for 5, 30 or 60 minutes. Juice and semen were then 
removed by washing and immobilised virus cultured with C8166 T cells for 7 days. Viral replication was determined by meas-
urement of RT in culture supernatants. LiJ concentrations tested were: A) 50%; B) 25%; C) 10%; and D) 5%. Data shown are 
expressed as percentage infection (when compared to an untreated virus control) and represent the mean ± SEM of n = 3 
(25% seminal plasma) or n = 5 (50% or no seminal plasma) independent experiments where each condition was tested in trip-
licate. Statistical analysis (ANOVA with Bonferroni post tests) was performed comparing LiJ treated samples and an untreated 
viral control, and comparing samples in the presence (2 concentrations) or absence (LiJ only) of seminal plasma. Those condi-
tions causing statistically significant differences are marked with asterisks (* p < 0.05; ** p < 0.01; *** p < 0.001) and are colour 
coded (red: juice only; dark blue: LiJ with 50% seminal plasma; light blue: LiJ with 25% seminal plasma).
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utive days. In neither treatment regime was 5% LiJ seen to
cause any detrimental effects.
Discussion
It has long been recognized that HIV is inactivated by low
pH (<4.0) [6,13-15]. Therefore the reduction of vaginal
pH by LiJ provides the basis for its potential use as an anti-
HIV intervention strategy. However SP is known to have
significant buffering capacity to overcome the low vaginal
pH that would be hostile to sperm viability [16]. Such
neutralization of vaginal pH has been postulated as a pos-
sible co-factor for sexual transmission of HIV [17]. Fur-
thermore, it should be noted that an evaluation of 19
varieties of lime found worldwide (obtained from the
USDA Repository in California), demonstrated significant
variation in colour, size, and the volume and pH of
extracted juice (data not shown). In particular, "sour"
limes had a very different pH to "sweet" limes (pH 2.7 ±
0.2 versus 6.2 ± 0.2; data not shown).
A previous report has demonstrated that 20% LeJ was suf-
ficient to reduce the pH of SP from 8.4 to 4.1 [18], sup-
porting its potential use as an acidic douche to reduce
pregnancy and STD transmission. Indeed, we also
observed that 50% sour LiJ significantly reduced the pH of
semen from pH 7.6 to 3.2 (data not shown). Furthermore,
20% LeJ or LiJ was sufficient to immobilise sperm within
1 minute [18] (Doncel, unpublished), suggesting that
both LeJ and LiJ could have spermicidal activity in vivo. LiJ
has previously been reported to exhibit potent virucidal
activity against HIV, with 20% LiJ inactivating 80% of HIV
within only 2 minutes and 10% juice in 60 minutes [19].
Data presented here support these findings, with concen-
Toxicity of lime on cervical epithelial cellsFigure 4
Toxicity of lime on cervical epithelial cells. Cervical 
epithelial cells (ME180) were exposed to LiJ (diluted using 
normal saline) for 5 (red circles), 30 (blue circles) or 60 
(green circles) minutes. Juice was then removed by washing 
and tissue viability assessed by the method of MTT dye 
reduction. Data shown are expressed as percentage viability 
(when compared to an untreated control) andrepresent the 
mean ± SEM of n = 4 independent experiments where each 
condition was tested in quadruplicate. The 50% toxic dose 
(TD50) of LiJ was determined using non-linear regression 
analysis.
Toxicity of lime juice on cervicovaginal and penile tissueFigure 3
Toxicity of lime juice on cervicovaginal and penile tissue. (A) Human cervicovaginal and (B) penile tissue explants were 
exposed to LiJ (diluted using normal saline) for 5, 30, 60 or 120 minutes. Juice was then removed by washing and tissue viability 
assessed by the method of MTT dye reduction. Data shown are expressed as percentage viability (when compared to an 
untreated control) andrepresent the mean ± SEM of n = 2 (cervicovaginal) or n = 3 (penile) independent tissue donors where 
each condition was tested in triplicate. Statistical analysis (ANOVA with Bonferroni post tests) was performed comparing LiJ 
treated samples with an untreated control. Those conditions causing statistically significant differences are marked with an 
asterisk (* p < 0.05; ** p < 0.01; *** p < 0.001). (C) The 50% toxic dose (TD50) of LiJ was determined using non-linear regres-
sion analysis for cervicovaginal (red circles) and penile (blue circles) tissue.
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trations of 50% and 5% LiJ able to inactivate HIV in vitro
within 5 and 30 minutes, respectively. However, whilst
others have suggested that LiJ retains its activity in the
presence of SP [19], we found its antiviral activity to be
severely reduced by this fluid (25 or 50% SP), requiring
the maintenance of a 1:1 mixture of neat LiJ and neat SP
for more than 5 minutes (and up to 30 minutes) to fully
inactivate HIV. The reduction in the inhibitory activity of
LiJ in the presence of SP is mostly linked to its buffering
capacity, suggesting that the main antiviral activity of LiJ
is mediated by low pH. This is in agreement with previous
studies that have shown LiJ, unlike pomegranate juice, has
no effect on gp120-CD4 interaction [20].
Whilst the use of LiJ may appear to be acceptable to Nige-
rian FSW [11], data from clinical studies have already
raised questions as to its safe use in areas of high HIV prev-
alence. Nineteen percent of women in the Nigerian cohort
reported pain following the use of LiJ/LeJ [11], however
no information was acquired about less "serious" but
uncomfortable side effects such as vaginal dryness, itching
or burning. Application of LiJ via tampon insertion or
douching has been evaluated under more controlled con-
ditions and compared with application of water alone.
Both LiJ and water were found to cause mild and transient
side effects in 70% of women, including vaginal dryness,
itching and burning, but burning and dryness occurred
more frequently in women using 20% LiJ [21]. Evaluation
of higher LiJ concentrations (50 and 100% via douching
or tampon application) found more adverse events,
including deep epithelial disruption, made worse if appli-
cation occurred via tampon use [22]. Cervicovaginal lav-
ages of women using LiJ for seven days showed high levels
of pro-inflammatory cytokines such as IL-1, IL-6, and IL-8
and increased numbers of CD45-positive leukocytes, indi-
cating the presence of a mucosal inflammatory response.
Furthermore, a recent cross-sectional observational study
of 374 FSW in Nigeria found a statistically significant
association between use of LeJ/LiJ (n = 81) and the pres-
ence of cervicovaginal intraepithelial neoplasia (CIN)
[23]. However, another study questioned 398 FSW about
their use of LiJ/LeJ (89 LiJ/LeJ users vs 312 non-users) and
related this to the prevalence of HIV and other STDs.
Whilst B. vaginosis appeared to show an association with
LiJ/LeJ usage (55.8% in users versus 44% in non-users),
this did not reach statistical significance (p = 0.06). Fur-
thermore, there were no associations between use of citrus
Toxicity of lime juice following topical application onto reconstructed cervicovaginal epitheliFigure 5
Toxicity of lime juice following topical application 
onto reconstructed cervicovaginal epithelia. Recon-
structed cervicovaginal epithelial tissues (MatTek Corpora-
tion) were exposed to LiJ (diluted using normal saline) for 5, 
30, 60 or 120 minutes. Juice was then removed by washing 
and tissue viability assessed by the method of MTT dye 
reduction. Data shown are expressed as percentage viability 
(when compared to an untreated control) andrepresent the 
mean ± SEM of n = 3 independent experiments. Statistical 
analysis was completed using ANOVA with Bonferroni post 
tests and statistically significant changes marked with * (p < 
0.05) or ** (p < 0.01).
Toxicity of lime juice following repeat topical application onto a reconstructed cervicovaginal epitheliumFigure 6
Toxicity of lime juice following repeat topical applica-
tion onto a reconstructed cervicovaginal epithelium. 
Reconstructed cervicovaginal epithelial tissues (MatTek Cor-
poration) were repeatedly exposed to LiJ (diluted using nor-
mal saline) for 30 minutes. Exposure occurred either: (A) 
once daily for 5 days; or (B) 5 times in one day (30 minute 
exposure, wash, culture for 1 hour then repeat exposure). 
After the final exposure, juice was removed by washing and 
epithelial viability assessed by the method of MTT dye reduc-
tion. Data shown are expressed as percentage viability (when 
compared to an untreated control) andrepresent the mean ± 
SEM of n = 2 independent experiments where each condition 
was tested in triplicate, except for 25% LiJ exposed repeat-
edly in one day which was only tested in one experiment. 
Statistical analysis was performed (ANOVA with Bonferroni 
post tests) to compare LiJ treated wells and an untreated 
control, and statistically significant changes are marked with 
** (p < 0.01); or *** (p < 0.001). ND: not determined (due to 
only one dataset).
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douching and other STDs, nor the prevalence of HIV-1
infection between LiJ/LeJ users (48.8%) and non-users
(48.2%) [24]. However, neither of these studies was able
to control for frequency of condom use, timing of LiJ/LeJ
douching and the degree to which the citrus juice was
diluted [23,24].
In vitro studies presented here suggest that an intact cervi-
covaginal epithelium is relatively resilient to the toxic
effects of LiJ. Reconstructed cervicovaginal epithelial cul-
tures were able to tolerate application of 50% LiJ for 30
minutes in the absence of significant toxicity. However,
viability was significantly reduced following longer expo-
sures. Furthermore, repeated exposure of an intact epithe-
lium to only 25% LiJ resulted in a significant loss of
viability. In experiments using non-polarized cervicovagi-
nal tissue explants, the toxic nature of LiJ was more appar-
ent, with a 30 minute exposure to 10% LiJ causing
significant toxicity, suggesting that toxicity would be
higher where the cervicovaginal mucosa was damaged.
This effect was also observed using penile explant tissue,
suggesting that male partners would also be susceptible to
the toxicity of LiJ. Cervicovaginal epithelial cell monolay-
ers were highly susceptible to LiJ induced toxicity. Other
reports have also demonstrated that LiJ is extremely toxic
to both cervical tissue and T cells in vitro [25]. Such effects
would be enhanced in women with cervical ectopy (a con-
dition common in young women where the more fragile
single layered epithelium of the endocervix displaces the
stratified epithelium of the ectocervix) or in the presence
of pre-existing ulcerative STDs or microtrauma induced
during coitus. This is emphasized by reports that up to
19% of women found the use of LiJ as a douche painful
[11].
These observations have important implications for the
use of LeJ/LiJ or other acidic solutions as potential inter-
vention strategies to reduce the risk of HIV transmission.
Firstly, there is no evidence to show that vaginal douch-
ing, especially if performed before sexual intercourse, can
maintain a volume of LiJ in the presence of cervicovaginal
secretions to provide a 1:1 ratio (equivalent to 50% LiJ)
with an infectious ejaculate (2–6 ml) for greater than 5
minutes (and up to 30 minutes). Furthermore, as non-
Clade B HIV isolates have been shown to be less sensitive
to the effects of pH [10], more juice or longer exposure
times may be required to inactivate virus from other
clades of HIV. For this approach to be successful, an acidic
douche must distribute evenly throughout the vaginal
lumen and effectively neutralise semen at all possible por-
tals of virus entry. If used prior to coitus, the antiviral effi-
cacy of this approach would depend on the time period
between douching and exposure to an infectious ejacu-
late, potential leakage of the LiJ from the vagina in the pre-
ceding interval, dilution by cervicovaginal secretions
induced by sexual arousal, and the re-equilibrium of vag-
inal pH with time. Measurement of vaginal pH one hour
after the first 100% LiJ application in the clinical safety
study mentioned above revealed only a small drop in
baseline pH (mean = 0.51 units), in the absence of semen,
reinforcing the notion that, applied prior to intercourse,
LiJ is unlikely to be effective in inactivating HIV [22]. Fur-
thermore, animal efficacy studies have consistently dem-
onstrated a >1000 fold difference between in vitro and in
vivo activity of compounds [4]; thus it is highly likely that
even neat LiJ would be far lower than the concentration
required to inactivate an infectious ejaculate in vivo. There-
fore, the use of LeJ/LiJ to prevent HIV transmission lacks
biological plausibility. Furthermore, data presented here
suggest that repeated application of LeJ/LiJ is likely to
result in epithelial damage. While the consequences of
such damage on susceptibility to HIV transmission or
other STDs are unknown, they should be cause for serious
concern in high risk populations.
Conclusion
In conclusion, our preclinical evaluation of the virucidal
activity and cytotoxicity of LiJ have identified potential
safety concerns for the use of LiJ as a vaginal douche in
individuals at risk of HIV infection. The results also fail to
demonstrate biological plausibility for the use of vaginal
douching with LiJ as an intervention strategy to prevent
HIV transmission.
Methods
Cell and virus culture
C8166 and PM-1 cells (AIDS reagent project, National
Institute for Biological standards and control, Potters Bar,
UK) were grown in continual culture (RPMI 10% [RPMI
1640 medium supplemented with 10% fetal bovine
serum, penicillin, streptomycin and L-glutamine]) and
passaged every 3–4 days. Adherent ME180 monolayers
(derived from a highly invasive squamous cell carcinoma
of the cervix; American Type Culture Collection (ATCC),
Rockville, MD) were grown in continual culture (DMEM
10% [Dulbecco's modified Eagle's Medium supple-
mented with 10% fetal calf serum, penicillin, streptomy-
cin and L-glutamine]) and passaged every 3–4 days.
ME180 cells were treated with 1× trypsin/EDTA (4 ml per
75 cm2 flask for approximately 5 minutes) to allow
detachment of cells and passage (approximately 1 in 10)
twice weekly. HIV-1 strains used were grown either in phy-
tohaemagglutinin (PHA)-stimulated peripheral blood
mononuclear cells (HIV-1BaL), or PM-1 cells (HIV-1BaL and
HIV-1RF). Cell-free viral stocks were passed through 0.2μm pore-size filters. Infection was monitored by viral
reverse transcriptase (RT) released into culture superna-
tants [26].
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Lime Juice (LiJ)
Sour limes were purchased at a local grocery store. They
were cut in half and manually squeezed. The resulting LiJ
was filtered through a Whatman number 1 paper, and
residual pulp and seeds were discarded. The LiJ of twelve
limes was processed in this manner, pooled, aliquoted
and stored frozen at -80°C until use. We cannot exclude
the possibility that some antiviral activity may have been
adsorbed by the filter paper, but consider this to be highly
unlikely. The pH of the LiJ was 2.4 ± 0.0 (mean ± S.D.)
which falls within the normal range for sour limes (pH
2.3–3.1). The seminal plasma used in this study immedi-
ately raised the pH of LiJ, yielding values >4.0 and >5.0,
respectively, at 1:4 and 1:8 lime:semen proportions.
Supply and culture of human samples
(a) Cervicovaginal tissue
Ectocervical or vaginal tissue was obtained from women
undergoing planned therapeutic hysterectomy at St
George's, St Helier's and Kingston Hospitals (London,
UK) (written consent was obtained from all tissue donors
according to the local Research Ethics Committee). Cervi-
covaginal tissue comprising both epithelium and stroma
was cut into 3 mm explants prior to culture in 96 well, flat
bottom tissue culture plates in RPMI 10%, as previously
described [27-30].
(b) Penile glans tissue
Penile tissue was obtained from gender reassignment sur-
gery at Charing Cross Hospital (written consent was
obtained from all tissue donors according to the local
Research Ethics Committee). Penile glans tissue compris-
ing both epithelium and stroma was cut into 3 mm
explants and cultured as described for cervicovaginal tis-
sue [31].
(c) Seminal plasma (SP)
Semen samples were obtained from healthy normo-
zoospermic donors participating in a research protocol
approved by the Eastern Virginia Medical School Institu-
tional Review Board (IRB). Samples were centrifuged at
500 g for 10 minutes following liquefaction, and SP was
collected from the supernatant. SP from different donors
was pooled, aliquoted and stored frozen at -80°C until
use. We have not assessed the effects of LiJ on non-lique-
fied semen and cannot exclude that this might behave dif-
ferently.
Supply and culture of reconstructed cervicovaginal epithelium
Reconstructed squamous "cervicovaginal" type epithe-
lium cultures, derived from normal human ectocervical
cells (NHEC) isolated from single donor adult human
ectocervical tissue, were purchased from MatTek Corpora-
tion, USA. Cultures, supplied in 24-well tissue culture
inserts, were of multilayer thickness, typically 10–16 cell
layers of non-cornified tissue by histology. Cultures were
shipped for use at 4°C on medium-supplemented, agar-
ose gels in 24-well plates. Typically, shipments were sent
(from the USA) on a Monday, arriving at the lab (in the
UK) on Wednesday afternoon. On arrival, cultures were
first allowed to equilibrate to room temperature for 1
hour, and then culture inserts carefully moved into 24-
wells containing 300 μl pre-warmed culture media (RPMI
10%), ensuring no transfer of the transport agarose. Cul-
tures were then cultured overnight at 37°C ready for use
the following day.
Determination of virucidal activity
(a) T cell assay: solid-phase immobilisation of HIV-1
HIV was immobilised onto the solid phase of 96-well flat-
bottomed tissue culture plates coated with poly L-lysine
(PLL; 50 μg/ml in PBS) for 1 hour at room temperature
[6]. Following washing (1 × 200 μl PBS), wells were incu-
bated with HIV-1RF (50 μl; 103 × TCID50) for 1 hour at
37°C after which unbound virus was removed by washing
(2 × 200 μl PBS). Immobilised virus, in the absence or
presence of 50% SP (this was always added to the wells
first), was treated with LiJ (5–50% final concentration,
diluted as necessary in 0.154 M NaCl [normal saline]) for
5, 30, 60 or 120 minutes at 37°C. LiJ/SP was removed by
washing (4 × 200 μl PBS) and virus cultured with C8166
(200 μl, 4 × 104 cells/well). Viral replication was deter-
mined following 7 days in culture by measurement of
reverse transcriptase activity in culture supernatants [26].
(b) Cervicovaginal tissue assay
HIV-1BaL (104 × TCID50) was incubated with diluted LiJ
(final concentrations of 50, 25, 10, 5 or 0% LiJ, diluted in
RPMI 10%) for 5, 30, 60 or 120 minutes. Cervicovaginal
tissue explants were then exposed to 200 μl of the virus/
LiJ incubate (pre-diluted 1/10 to reduce the potentially
toxic effects of LiJ to tissue) and incubated at 37°C for 2
hours. Tissue explants were then washed (4 × 200 μl PBS)
and cultured for 10 days with 50% media feeds every 2–3
days. Viral infection was determined by the release of p24
antigen released into culture supernatants (p24 antigen
ELISA, Beckman Coulter, carried out according to the
manufacturer's protocol). To ensure the absence of infec-
tion was not due to the toxic effects of LiJ, replicate tissues
were exposed to diluted LiJ alone for 2 hours and tissue
viability determined by MTT dye reduction as described
below.
Toxicity of lime juice
(a) Toxicity to human genital tissue
Genital tissue explants (cervicovaginal or penile) were
exposed to diluted LiJ (200 μl; 5–50% final concentration,
diluted in RPMI 10%) for 5, 30, 60 or 120 minutes. LiJ
was then removed by washing (4 × 200 μl PBS) and via-
bility determined using the MTT (3 [4,5-dimethylthiazol-
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2-yl]-2,5 dipbenyltetrazolium bromide or thiazolyl blue)
dye reduction method. Briefly, explants were exposed
(submerged) to 0.5 mg/ml MTT for 2 hours at 37°C when
live cells can reduce the MTT dye into a methanol soluble
formazan product. Explants were then blotted to remove
excess liquid, weighed, transferred into 1 ml methanol
and incubated overnight at room temperature in the dark.
The absorbance of the methanol containing the MTT-for-
mazan product was determined at 570 nm and the % via-
bility per mg tissue calculated by the comparison of test
samples to explants not exposed to LiJ.
(b) Toxicity to cervical epithelial cell monolayers
ME180 cells (0.2 × 105 cells/well) were seeded into 96-
well plates and cultured overnight to approximately 60%
confluency. Media was removed and cells exposed to LiJ
(100 μl; 5–50% final concentration, diluted in 0.154 M
NaCl) for 5, 30 or 60 minutes at 37°C. Compound was
then removed by washing (4 × PBS) and media containing
MTT (200 μl; 0.5 mg/ml) added to each well. Following
incubation at 37°C for 2 hours, media was removed and
cells solubilised in 100 μl lysis buffer (98% isopropanol/
2% 2 N HCl). Well contents were mixed to evenly distrib-
ute the dye, and the absorbance determined at 570 nm.
(c) Toxicity to a reconstructed cervicovaginal epithelium
To assess the epithelium viability following topical appli-
cation of LiJ, reconstructed cervicovaginal epithelium cul-
tures were exposed to a topical application of LiJ (100 μl;
5–50% final concentration, diluted in 0.154 M NaCl) for
5–120 minutes. LiJ was then carefully removed by wash-
ing (2 × 200 μl PBS) and epithelium viability determined
using the method of MTT dye reduction. Briefly, cultures
were exposed to MTT (0.5 mg/ml in RPMI 10%; 300 μl)
from the basolateral surface and incubated for 2 hours at
37°C. Cultures were then transferred into culture plates
containing 1 ml methanol and the insert also filled with 1
ml methanol (such that there was 2 ml total/well, totally
immersing the insert). Cultures were incubated for 2
hours (room temperature), before the dye was released by
breaking the culture insert membrane and mixing the
methanol to obtain a homogeneous solution. Sample
absorbance was determined at 570 nm using methanol as
a blank. % viability of the lime treated samples was deter-
mined by comparing to a media only treated control cul-
ture.
To determine any cumulative effect following repeat topi-
cal exposure, reconstructed cervicovaginal epithelial cul-
tures were exposed to LiJ (5, 10 or 25% final
concentration, diluted in 0.154 M NaCl) either repeatedly
over 1 day, or once daily for 5 days. In each case, cultures
were exposed to LiJ for 30 minutes after which LiJ was
removed by washing (4 washes with PBS). Epithelia were
then cultured in the absence of LiJ for either 1 hour or
overnight. This was repeated for a total of five LiJ applica-
tions and epithelial viability was determined immediately
following removal of the fifth application as described
above.
Statistical analyses
50% inhibitory concentration (IC50) and toxic dose
(TD50) analysis was completed using non-linear regres-
sion analysis (Graphpad PRISM, GraphPad Software,
Inc.). Data was also analysed by ANOVA (with Bonferroni
post tests) to determine the effect of LiJ treatment on sam-
ples, and to determine the effect of the presence of SP on
LiJ activity.
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